Rigel Launches VEPPANU for ESR1-Mutated Breast Cancer
South San Francisco, California, August 13, 2026 Rigel Pharmaceuticals, Inc. announced the U.S. commercial availability of VEPPANU™ (vepdegestrant) for...
Cancer Treatment
Advertisement
Mendaera Reports 98% Success for Focalist System
San Mateo, California, August 12, 2026 Mendaera Inc. announced results from a new peer-reviewed prospective multispecialty study showing that...
Freenome Gains FDA Breakthrough Device Designation
Brisbane, California, August 12, 2026 Freenome, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Taiho Oncology Advances Zipalertinib in Phase 3 Trial
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
Kura Oncology Publishes Ziftomenib Data in Blood
SAN DIEGO, August 10, 2026 Kura Oncology, Inc. announced the publication of new research in Blood detailing the discovery...
Advertisements
Silence Therapeutics Reports Positive Divesiran Phase 2 Data
London, August 10, 2026 Silence Therapeutics plc announced positive topline results from the Phase 2 SANRECO trial of divesiran...
BeOne Medicines Partners with Revolution Medicines on RAS Cancer Therapies
San Carlos, Calif. & Redwood City, Calif., August 10, 2026 BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a...
Acarix Wins UAE Approval for AI-Powered CADScor System
United Arab Emirates, August 10, 2026 Acarix AB has announced that its CADScor® System, an artificial intelligence-enabled point-of-care diagnostic...
Innovent and Daiichi Sankyo Partner on VANFLYTA in China
SAN FRANCISCO, USA and SUZHOU, China, August 9, 2026 Innovent Biologics and Daiichi Sankyo have entered into an exclusive...
Ratio Therapeutics Raises $70 Million to Advance Radiotherapeutics
BOSTON, July 31, 2026 Ratio Therapeutics announced the successful closing of a $70 million Series C financing, increasing the...
Advertisement
